Enanta Pharmaceuticals Inc (ENTA) : Hays Advisory reduced its stake in Enanta Pharmaceuticals Inc by 14.12% during the most recent quarter end. The investment management company now holds a total of 172,557 shares of Enanta Pharmaceuticals Inc which is valued at $3,713,427 after selling 28,369 shares in Enanta Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Enanta Pharmaceuticals Inc makes up approximately 0.56% of Hays Advisory’s portfolio.
Other Hedge Funds, Including , Acadian Asset Management reduced its stake in ENTA by selling 117,738 shares or 14.57% in the most recent quarter. The Hedge Fund company now holds 690,136 shares of ENTA which is valued at $14,851,727. Enanta Pharmaceuticals Inc makes up approx 0.07% of Acadian Asset Management’s portfolio.Fox Run Management L.l.c. reduced its stake in ENTA by selling 1,000 shares or 9.26% in the most recent quarter. The Hedge Fund company now holds 9,800 shares of ENTA which is valued at $210,896. Enanta Pharmaceuticals Inc makes up approx 0.10% of Fox Run Management L.l.c.’s portfolio.Eqis Capital Management reduced its stake in ENTA by selling 5,510 shares or 10.69% in the most recent quarter. The Hedge Fund company now holds 46,015 shares of ENTA which is valued at $1,010,950. Enanta Pharmaceuticals Inc makes up approx 0.07% of Eqis Capital Management’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in ENTA in the latest quarter, The investment management firm added 2,355 additional shares and now holds a total of 4,418 shares of Enanta Pharmaceuticals Inc which is valued at $103,116.
Enanta Pharmaceuticals Inc opened for trading at $21.35 and hit $21.59 on the upside on Wednesday, eventually ending the session at $21.52, with a gain of 0.89% or 0.19 points. The heightened volatility saw the trading volume jump to 3,78,739 shares. Company has a market cap of $408 M.
On the company’s financial health, Enanta Pharmaceuticals Inc reported $-0.09 EPS for the quarter, missing the analyst consensus estimate by $ -0.19 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $0.10. The company had revenue of $13.00 million for the quarter, compared to analysts expectations of $16.80 million. The company’s revenue was down -77.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.49 EPS.
Many Wall Street Analysts have commented on Enanta Pharmaceuticals Inc. Enanta Pharmaceuticals Inc was Downgraded by JMP Securities to ” Mkt Perform” on Apr 28, 2016.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.